Show simple item record

dc.contributor.authorSleijfer, Sen_US
dc.contributor.authorRizzo, Een_US
dc.contributor.authorLitière, Sen_US
dc.contributor.authorMathijssen, RHJen_US
dc.contributor.authorJudson, IRen_US
dc.contributor.authorGelderblom, Hen_US
dc.contributor.authorVan Der Graaf, WTAen_US
dc.contributor.authorGronchi, Aen_US
dc.date.accessioned2018-03-28T11:44:24Z
dc.date.issued2018-08en_US
dc.identifier.citationActa oncologica (Stockholm, Sweden), 2018, 57 (8), pp. 1117 - 1126en_US
dc.identifier.issn0284-186Xen_US
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/1617
dc.identifier.eissn1651-226Xen_US
dc.identifier.doi10.1080/0284186x.2018.1449248en_US
dc.description.abstractINTRODUCTION:As both anti-tumour effects and toxicity are thought to be dose-dependent, patients with the greatest toxicity may also have the best outcome. We assessed whether severity of doxorubicin-induced hematological toxicity is associated with outcome in advanced soft tissue sarcoma (STS) patients. In addition, risk factors for hematological toxicity were explored. METHODS:Worst haematological toxicities (anaemia, leukopenia, neutropenia and thrombocytopenia) seen during treatment were scored according to CTCAE toxicity score. Differences in overall survival (OS), progression free survival (PFS) and response rate (RR) between patients with or without high haematological toxicity (grades 0-2 vs. 3-4) were assessed using conventional statistical tests. Associations between baseline characteristics and hematological toxicity were established using logistic multivariate regression. RESULTS:In 557 patients eligible for this analysis, 47.2% of the patients received at least six cycles of treatment; 45% stopped treatment early due to progression, 3% because of toxicity. Relative dose intensity (RDI) was constant over the cycles. OS, PFS, and RR did not differ between patients with grade 3/4 toxicity during treatment versus those with grade 1/2. Risk factors for grade 3/4 haematological toxicity, in particular neutropenia, were age above 60 years, low BMI, and female gender. CONCLUSION:In this large series, risk factors for haematological toxicity in STS patients receiving doxorubicin monotherapy were revealed. The finding that there was no association between outcome and haematological toxicity during doxorubicin treatment may be useful to reassure advanced STS patients that failure to experience haematological toxicity during treatment does not equate to under-treatment.en_US
dc.formatPrint-Electronicen_US
dc.format.extent1117 - 1126en_US
dc.languageengen_US
dc.language.isoengen_US
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en_US
dc.subjectHumansen_US
dc.subjectSarcomaen_US
dc.subjectBone Neoplasmsen_US
dc.subjectHematologic Diseasesen_US
dc.subjectDoxorubicinen_US
dc.subjectAntibiotics, Antineoplasticen_US
dc.subjectDisease-Free Survivalen_US
dc.subjectTreatment Outcomeen_US
dc.subjectRetrospective Studiesen_US
dc.subjectAdulten_US
dc.subjectMiddle Ageden_US
dc.subjectFemaleen_US
dc.subjectMaleen_US
dc.titlePredictors for doxorubicin-induced hematological toxicity and its association with outcome in advanced soft tissue sarcoma patients; a retrospective analysis of the EORTC-soft tissue and bone sarcoma group database.en_US
dc.typeJournal Article
dcterms.dateAccepted2018-02-23en_US
rioxxterms.versionofrecord10.1080/0284186x.2018.1449248en_US
rioxxterms.licenseref.startdate2018-08en_US
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfActa oncologica (Stockholm, Sweden)en_US
pubs.issue8en_US
pubs.notesNo embargoen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical and Translational Sarcoma
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Sarcoma Clinical Trials
pubs.publication-statusPublisheden_US
pubs.volume57en_US
pubs.embargo.termsNo embargoen_US
icr.researchteamClinical and Translational Sarcomaen_US
icr.researchteamSarcoma Clinical Trialsen_US
dc.contributor.icrauthorvan der Graaf, Wilhelminaen_US
dc.contributor.icrauthorJudson, Ianen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

http://creativecommons.org/licenses/by/4.0/
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by/4.0/